Source-grounded facts extracted from Acumen Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Acumen Pharmaceuticals, Inc. shareholders approved Approval of the Company's Amended and Restated 2021 Equity Incentive Plan. at the 2026-06-03 meeting.
“Proposal No. 3 : The stockholders approved the Company’s Amended and Restated 2021 Equity Incentive Plan. The votes were cast as follows: Votes For Votes Against Abstained Broker Non-Votes Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan 30,731,776 6,618,621 24,134 19,676,925”
Acumen Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
“Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 56,934,900 113,074 3,482”
Acumen Pharmaceuticals, Inc. shareholders approved Election of three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-03 meeting.
“Proposal No. 1: The stockholders elected three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes George Golumbeski, Ph.D. 37,305,711 68,820 19,676,925”
Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2025 results: net income Net loss was $121.3 million.
“Net loss was $121.3 million for the year ended Dec. 31, 2025, compared to $102.3 million for the year ended Dec. 31, 2024.”
Acumen Pharmaceuticals, Inc. issued 10,833,331 shares of common stock to certain institutional accredited investors named therein for $3.30 per Share.
“On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.”
Acumen Pharmaceuticals, Inc. entered into Registration Rights Agreement with certain institutional accredited investors valued at registration for resale of the Shares pursuant to a registration statement to be filed with the SEC (effective 2026-03-13).
“In connection with the Private Placement, the Company and the Investors entered into a Registration Rights Agreement, dated March 13, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) no later than two business days after the date on which the Company files with the SEC its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.”
Acumen Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million (effective 2026-03-13).
“On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.”
Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.
“Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.”
Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $52.4 million.
“Net loss for the year ended December 31, 2023 was $52.4 million”
Daniel O'Connell changed role as Chief Executive Officer at Acumen Pharmaceuticals, Inc..
“Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.”
James Doherty was appointed as President and Chief Development Officer at Acumen Pharmaceuticals, Inc..
“James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.”
Acumen Pharmaceuticals, Inc. reported financial results for Q3 2023.
“On November 13, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023.”
Acumen Pharmaceuticals, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at seven figure upfront payment (effective 2023-11-05).
“On November 5, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Non-exclusive Collaboration and License Agreement (the “ Agreement ”) with Halozyme, Inc. (“ Halozyme ”).”
Acumen Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $11.6 million for the three-month period ended June 30, 2023.
“Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended June 30, 2023.”
Acumen Pharmaceuticals, Inc. entered into Underwriting Agreement with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (effective 2023-07-18).
“On July 18, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (the “Underwriters”), relating to a public offering (the “Offering”) of 16,774,193 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $7.75 per share.”
Acumen Pharmaceuticals, Inc.: Amended certificate of incorporation to reflect Delaware law provisions allowing for exculpation of officers (effective 2023-06-06).
“On June 6, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) held its 2023 annual meeting of stockholders (the “ Annual Meeting ”). As described in Item 5.07 below, the Company’s stockholders approved the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ” and, as amended, the “ Amended Certificate of Incorporation ”) to reflect Delaware law provisions allowing for the exculpation of officers.”
Acumen Pharmaceuticals, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to reflect Delaware law provisions allowing for exculpation of officers at the 2023-06-06 meeting.
“Proposal No. 3: The stockholders approved an amendment to the Company’s Certificate of Incorporation to reflect Delaware law provisions allowing for the exculpation of officers. The votes were cast as follows: Votes For Votes Against Abstained Amendment to Certificate of Incorporation 27,061,448 39,649 892”
Acumen Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
“Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 36,099,071 185 214”
Acumen Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-06-06 meeting.
“Proposal No. 1: The stockholders elected two nominees to serve as Class II directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Derrell Porter, M.D. 27,096,949 5,040 Laura Stoppel, Ph.D. 24,440,807 2,661,182”
Acumen Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income $11.3 million.
“Net loss was $11.3 million for the three-month period ended March 31, 2023”
Acumen Pharmaceuticals, Inc. amended Sales Agreement with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, BTIG, LLC valued at aggregate offering price of up to $50,000,000 (effective 2023-04-27).
“On April 27, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an amendment (“Amendment No. 1”) to the Sales Agreement, dated as of July 1, 2022 (the “Sales Agreement” and, as amended by Amendment No. 1, the “Amended Sales Agreement”) with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated and BTIG, LLC (collectively referred to as “Sales Agents” and each individually a “Sales Agent”), pursuant to which the Company may sell its common stock, par value $0.0001 per share, from time to time through the Sales Agents in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1934, as amended (the “Securities Act”).”
Acumen Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
“On March 27, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the year ended December 31, 2022.”
Acumen Pharmaceuticals, Inc.: Adopted amended and restated bylaws including enhancements to stockholder nomination procedures and updates for universal proxy rules and DGCL changes (effective 2023-03-09).
“On March 9, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Acumen Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.”
Dr. Derrell Porter was appointed as director at Acumen Pharmaceuticals, Inc..
“On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).”
Acumen Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $10.7 million.
“Net loss was $10.7 million for the three-month period ended September 30, 2022”
Jeffrey Sevigny resigned as Director at Acumen Pharmaceuticals, Inc..
“On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.